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116 Kimball et alResults: For 2510 patients, 5-year cumulative incidence was 22.2% (95% confidence interval [CI] 20.3%-
24.2%) for serious adverse events; 6.5% (95% CI 5.4%-7.7%) for serious infectious events; 3.2% (95% CI
2.3%-4.1%) for malignancies excluding nonmelanoma skin cancer; 3.6% (95% CI 2.7%-4.5%) for
nonmelanoma skin cancer; 2.8% (95% CI 2.0%-3.6%) for coronary artery disease; 0.7% (95% CI 0.3%-
1.2%) for psoriasis worsening; 0.2% (95% CI 0.0%-0.4%) for central nervous system demyelinating disorder;
0.1% (95% CI 0.0%-0.3%) for lymphoma and for tuberculosis; and 0.1% (95% CI 0.0%-0.2%) for
opportunistic infection and for lupus; 55 fatal events were reported. Rates of malignancies, lymphomas,
nonmelanoma skin cancer, and hospitalization-associated infections were not higher than expected relative
to administrative claims data. The percentage of patients rated as clear/almost clear was 12% at baseline,
which increased to 51% at month 6 and remained relatively stable throughout 5 years.Limitations: No internal comparator group was included; rare events may not have been detected.Conclusion: No new safety signals were observed with long-term, real-world etanercept use. ( J Am Acad
Dermatol 2015;72:115-22.)
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surveillance.Etanercept is a tumor necrosis factor (TNF)
blocker indicated for the treatment of adultsCAPSULE SUMMARY
d OBSERVE-5 evaluated long-term safety of
etanercept in 2510 patients.
d Rates of malignancies, lymphomas,
nonmelanoma skin cancer, and
hospitalization-associated infections
were not higher than expected relative
to claims data (standardized incidence
ratios\ 1.0).
d No new/unexpected safety signals were
noted for up to 5 years of real-world use
of etanercept.with chronic moderate to
severe plaque psoriasis
who are candidates for
systemic therapy or photo-
therapy, and for treatment
of rheumatoid arthritis,
polyarticular juvenile idio-
pathic arthritis, psoriatic
arthritis, and ankylosing
spondylitis.1 An analysis
of long-term safety in
506 patients with psoriasis
who initiated etanercept
in 2 phase-III clinical
trials showed a favo-
rable safety profile, with
no cumulative toxicity
noted for up to 4 years of treatment.2
Although short-term clinical trials provide impor-
tant information on the efficacy and safety of a drug,
long-term registry studies are also needed to detect
rare adverse events in a broader patient population.
OBSERVE-5 was a 5-year observational registry that
enrolled 2510 patients with plaque psoriasis who
received etanercept.3 We now report the final
analysis of OBSERVE-5 data representing long-
term, real-world experiencewith etanercept therapy.METHODS
Study design
OBSERVE-5 was a phase-IV, prospective, multi-
center, observational, surveillance registry and
has been previously described.4 Briefly, etanercept
was self-administered at the dose and regimendetermined by the investigator and patients
were evaluated at 6-month intervals for up to 5years. Patients could have
discontinued etanercept,
switched to another anti-
psoriatic therapy, used
etanercept in combination
with other antipsoriatic
therapies, or discontinued
any or all antipsoriatic treat-
ments during the study.
The study was approved
by institutional review
boards at all study sites.
Written informed consent was
provided by all patients
before initiation of any study-
related procedures. This
study was registered underClinicalTrials.gov identifier NCT00322439.Patients
As previously described,4 patients with plaque
psoriasis for whom etanercept therapy was indicated
per prescribing information and for whom the
treating physician decided to initiate, reinitiate, or
continue etanercept therapy according to usual care
were eligible. Initially, patients were etanercept-
na€ıve but a protocol amendment allowed patients
with prior etanercept exposure to enroll (capped at
50%). Patients were ineligible if they were contra-
indicated for etanercept treatment according to the
prescribing information,1 had been treated with
other TNF blockers or with commercial etanercept
before April 2004 in the United States or December
2005 in Canada (when etanercept was approved for
Abbreviations used:
BSA: body surface area
CI: confidence interval
EMI: event of medical interest
NMSC: nonmelanoma skin cancer
PGA: physician global assessment
SAE: serious adverse event
SIE: serious infectious event
SIR: standardized incidence ratio
TNF: tumor necrosis factor
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clinical studies.
Outcome measures
Serious adverse events (SAEs); serious infectious
events (SIEs), which included infectious events
requiring hospitalization; and events of medical
interest (EMIs) were reported and assessed
throughout the study and for 30 days after the
study. An event was considered to be an SAE if it
was fatal, was life-threatening, required hospitaliza-
tion, resulted in disability/incapacity, was a congen-
ital anomaly/birth defect, or was a significant
medical hazard. EMIs included malignancies
(including basal cell and squamous cell carcinomas);
tuberculosis; opportunistic infections treated with
intravenous therapy; histoplasmosis and coccidioi-
domycosis infections treated with oral antibiotics;
central nervous system demyelinating disorders;
lupus disease; coronary artery disease; and wors-
ening of psoriasis (change in psoriasis morphology
and withdrawal of therapy). An EMI was considered
to be an SAE if additional criteria such as death or
hospitalization occurred. Effectiveness outcomes
included changes in psoriasis-affected body surface
area (BSA), physician global assessment (PGA)
score,5 and Dermatology Life Quality Index score.6
External context analysis
Incidence rates of all malignancies (excluding
nonmelanoma skin cancer [NMSC]), lymphoma,
NMSC, and infectious events leading to hospitaliza-
tion were assessed in relation to corresponding rates
from the Truven Health MarketScan Commercial
Claims and Encounters and MarketScan Medicare
Supplemental databases using incidence rates based
on person-time of observation for malignancy out-
comes and person-time of exposure for the hospi-
talized infections. MarketScan databases collect
enrollment data, medical claims, and laboratory
and prescription data. For this analysis, MarketScan
patients were aged 18 years or older and 90 years
or younger; met the qualifying criteria between
January 1, 2006, and December 31, 2006 (enrollmentwindow); and had 12 months of continuous enroll-
ment before their index date to describe their med-
ical and treatment history (baseline period). The
primary comparator analysis was with patients in
MarketScan who received nonbiologic systemic
therapies (methotrexate, cyclosporine); additional
analyses were conducted with patients receiving
etanercept, phototherapy, other biologic therapies,
methotrexate only, all patients with psoriasis, and
the general population. Incidence rates from
MarketScan were calculated and age- and sex-
standardized to the OBSERVE-5 population for
each outcome of interest. Standardized incidence
ratios (SIRs) with 95% confidence intervals (CIs)
were calculated using MarketScan rates as the
reference.
Statistical considerations
A study size of 2500 patients was required by the
Food and Drug Administration. No statistical hypoth-
esis was tested in this observational study.
Descriptive statistics are provided for baseline char-
acteristics and outcome measures. The primary
analysis of safety end points was performed using
Kaplan-Meier methodology. Cumulative incidences
were calculated using 2 methods: first, by including
all time from first dose of etanercept to start date of
the first event occurrence, regardless of the pattern of
etanercept exposure (observation time); and second,
by excluding time intervals and corresponding
events when the patient was not on etanercept
(exposure time). For EMIs, survival estimates were
adjusted using left truncation methodology to
address potential survival bias introduced by the
inclusion of patients with prior etanercept exposure.
It was assumed that patients with prior etanercept
exposure who had experienced rare events or
malignancies would have permanently discontinued
treatment and would not have qualified to enter the
study. The left truncation technique accounts for this
conditional sampling. For example, a patient with 2
years of prior exposure before entering the registry
would begin follow-up in his or her third year since
becoming exposed; for such a patient, an event in
the second year of being followed up in the registry
would be counted as an event in the fourth year since
starting exposure.
RESULTS
Patients
This study was conducted at 375 sites (37 Canada,
338 United States). A total of 2511 patients enrolled in
OBSERVE-5 of whom 2510 received 1 or more doses
of etanercept; 1326 enrolled after the amendment
allowing prior etanercept exposure. In all, 664 (26%)
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Fig 1. Plaque psoriasis. Etanercept status by visit. The number of patients remaining in the
study (black bars) and those who remained on etanercept therapy (white bars) throughout the
5-year study is shown. BL, Baseline.
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enrolling in OBSERVE-5 and 1846 (74%) patients
were etanercept-na€ıve on enrollment. Baseline char-
acteristics have been previously described.4 Of all
patients, 1455 (58.0%) continued in the study until
the end of follow-up, 1042 (41.5%) discontinued
before the end of follow-up, and 13 patients did not
have discontinuation status because of early site
closure. At each study visit, 80% or more of patients
who continued on study also continued on etaner-
cept (Fig 1). A total of 164 patients received
etanercept continuously without interruption
throughout the study, 182 received etanercept
throughout the study with 1- to 30-day gaps (mean
16 total gap days) in etanercept therapy, and 63
received etanercept throughout the study with 31- to
60-day gaps (mean 58 total gap days) in etanercept
therapy. Of the patients who experienced gaps in
etanercept therapy, most had only 1 or 2 treatment
gaps.Serious adverse events
A total of 418 patients, on and off etanercept,
reported an SAE during the study (Table I). The
most commonly reported noninfectious SAEs
were myocardial infarction (0.7% of patients),
coronary artery disease (0.6%), and osteoarthritis
(0.6%) and the most common SIEs were pneu-
monia (1.2%) and cellulitis (0.9%). In all, 55
patients had a fatal event; of these, 17 were of
unknown cause. Four deaths were considered by
the investigator to be related to etanercept: brain
cancer and lung cancer, heart failure, osteomye-
litis and sepsis, and idiopathic pulmonary fibrosis.
The 5-year Kaplan-Meier cumulative incidence of
SAEs based on observation time was 22.2% (95%
CI 20.3%-24.2%) and the incremental yearly inci-
dence (data not shown) decreased during the
study (Table II).Serious infectious events
A total of 120 patients reported 1 or more SIEs and
94 patients reported an SIE leading to hospitalization
(Table I). The 5-year Kaplan-Meier cumulative inci-
dence for SIEs based on observation time was 6.5%
(95% CI 5.4%-7.7%) and the incremental yearly
incidence (data not shown) generally decreased
over time (Table II). The 5-year Kaplan-Meier cumu-
lative incidence for SIEs requiring hospitalization
was 5.2% (95% CI 4.1%-6.2%).
Events of medical interest
A total of 604 patients had 1ormore EMIs (Table I),
including 159 patients with an EMI that was consid-
ered by the investigator to be related to etanercept.
The 5-year Kaplan-Meier cumulative incidences
based on observation time were 0.1% (95% CI 0.0%-
0.3%) for tuberculosis (n = 2); 0.2% (95% CI 0.0%-
0.4%) for central nervous system demyelinating
disorder (n = 3); 0.1% (95% CI 0.0%-0.2%) for lupus
disease and for opportunistic infections (n = 1 each);
2.8% (95% CI 2.0%-3.6%) for coronary artery disease
(n = 46); and 0.7% (95% CI 0.3%-1.2%) for worsening
of psoriasis (n = 12). No case of histoplasmosis
or coccidioidomycosis was reported. The 5-year
Kaplan-Meier cumulative incidences based on obser-
vation time were 3.21% (95% CI 2.34%-4.08%) for
malignancy excluding NMSC; 3.60% (95% CI 2.69%-
4.50%) for NMSC; and 0.12% (95% CI 0.0%-0.29%) for
lymphoma (Table III).
External context
For the outcomes of malignancies excluding
NMSC, lymphoma, and NMSC, incidence rates for
registry patients were not higher than the rates of the
psoriasis population using nonbiologic systemic ther-
apies (primary comparator) or those receiving etaner-
cept in the MarketScan database (Table IV). Incidence
rates of SIEs requiring hospitalization in OBSERVE-5
Table I. Summary of serious adverse events, serious
infectious events, and event of medical interest
All patients
(N = 2510)
SAEs, patients reporting event, n (%) 418 (16.7)
Most common treatment-emergent SAEs,
n (%)
Pneumonia 30 (1.2)
Cellulitis 22 (0.9)
Myocardial infarction 17 (0.7)
Coronary artery disease 14 (0.6)
Osteoarthritis 14 (0.6)
Diverticulitis 11 (0.4)
Most common treatment-related
SAEs, n (%)
Pneumonia 8 (0.3)
Cellulitis 8 (0.3)
SIEs, patients reporting event, n (%) 120 (4.8)
Most common treatment-emergent SIEs,
n (%)
Pneumonia 30 (1.2)
Cellulitis 22 (0.9)
Diverticulitis 11 (0.4)
Staphylococcal infection 7 (0.3)
Sepsis 5 (0.2)
Appendicitis 4 (0.2)
Bronchitis 4 (0.2)
Herpes zoster 4 (0.2)
SIEs leading to hospitalization, n (%) 94 (3.7)
Pneumonia 28 (1.1)
Cellulitis 19 (0.8)
Diverticulitis 8 (0.3)
Sepsis 5 (0.2)
Appendicitis 4 (0.2)
Gastroenteritis 3 (0.1)
Staphylococcal infection 3 (0.1)
EMIs, patients reporting event, n (%) 604 (24.1)
Select EMIs, n (%)
Malignancy 122 (4.9)
NMSC 66 (2.6)
Coronary artery disease 49 (2.0)
Worsening of psoriasis 13 (0.5)
CNS demyelinating disorder 3 (0.1)
Lymphoma 2 (0.1)
Tuberculosis 2 (0.1)
Lupus disease 1 (\ 0.1)
Opportunistic infection 1 (\ 0.1)
Coccidioidomycosis 0
Histoplasmosis 0
Includes events counted beyond year 5 because of left truncation
adjustment in Kaplan-Meier analyses.
Includes patients on and off etanercept.
CNS, Central nervous system; EMIs, events of medical interest;
NMSC, nonmelanoma skin cancer; SAEs, serious adverse events;
SIEs, serious infectious events.
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Kimball et al 119were not higher than the rates from the primary
external comparator group based on patient-years of
etanercept exposure (SIR 0.34; 95% CI 0.26-0.43).Effectiveness outcomes
Mean baseline psoriasis-affected BSA was 12%
and 24% for patients receiving prior etanercept
and etanercept-na€ıve patients, respectively. Mean
psoriasis-affected BSA improved from 21% at base-
line to 8% at month 6, and remained stable
throughout 5 years (Fig 2, A). At baseline, 37% and
3% of patients who had received prior etanercept
and etanercept-na€ıve patients, respectively, had PGA
status of clear/almost clear (score of 0 or 1). The
percentage of all patients with PGA status of clear/
almost clear was 12% at baseline, which increased to
51% at month 6 and remained relatively stable
throughout 5 years (Fig 2, B). Mean Dermatology
Life Quality Index scores at baseline were 6.1 (SD
6.3) and 12.5 (SD 6.9) for patients who had received
prior etanercept and etanercept-na€ıve patients,
respectively. The mean score for all patients at
baseline was 10.8 (SD 7.3), which improved to 4.4
(SD 5.1) at month 6 and remained stable throughout
5 years (Fig 2, C ).
DISCUSSION
This assessment of long-term safety of etanercept
in patients with plaque psoriasis found that Kaplan-
Meier cumulative incidences of SAEs, SIEs, and SIEs
requiring hospitalization were low and incremental
yearly incidences decreased during the 5 years of the
registry. Using MarketScan data to provide age- and
sex-standardized expected incidence rates, observed
rates of malignancies, lymphomas, NMSC, and in-
fections requiring hospitalization in OBSERVE-5
were not higher than expected. Patients who had
received prior etanercept had generally better base-
line mean scores for BSA, PGA, and Dermatology
Life Quality Index assessments compared with pa-
tients who were etanercept-na€ıve at study entry.
Both groups had improvements from baseline in
these assessments, and by month 6, the 2 groups
were similar. The proportion of patients with PGA
status of clear/almost clear after month 6 was
approximately 45% to 50% in patients with and
without prior etanercept exposure, which was
higher than the rate seen with etanercept mono-
therapy in a large, real-world, cross-sectional study
(34%).7 Patients with up to 60-day gaps in etanercept
therapy demonstrated similar effectiveness as pa-
tients who remained on continuous etanercept
therapy.
The results for SAEs and SIEs in OBSERVE-5 were
similar to those reported in an integrated analysis of
safety, which examined data from 7 clinical trials that
lasted up to 2 years.8 In that analysis, rates of SAEs
and SIEs were comparable between placebo and
etanercept groups in short-term studies, and no
Table III. Kaplan-Meier incidence proportions of malignancies
Registry year
Based on observation time* Based on exposure timey
Patients with event, n Cumulative incidence, Q (95% CI) Patients with event, n Cumulative incidence, Q (95% CI)
All malignancies excluding NMSC
First year 7 0.0041 (0.0011-0.0072) 7 0.0033 (0.0004-0.0061)
Second year 12 0.0115 (0.0064-0.0167) 8 0.0090 (0.0039-0.0141)
Third year 15 0.0208 (0.0139-0.0277) 10 0.0156 (0.0085-0.0226)
Fourth year 6 0.0244 (0.0169-0.0319) 7 0.0230 (0.0142-0.0319)
Fifth year 11 0.0321 (0.0234-0.0408) 5 0.0304 (0.0195-0.0413)
Sixth year 7 0.0475 (0.0332-0.0617) 0 0.0304 (0.0195-0.0413)
Seventh year 1 0.0509 (0.0352-0.0666) 0 0.0304 (0.0195-0.0413)
Eighth year 1 0.0574 (0.0373-0.0775) 0 0.0304 (0.0195-0.0413)
Lymphoma
First year 1 0.0006 (0.0000-0.0018) 1 0.0007 (0.0000-0.0020)
Second year 0 0.0006 (0.0000-0.0018) 0 0.0007 (0.0000-0.0020)
Third year 1 0.0012 (0.0000-0.0029) 1 0.0016 (0.0000-0.0040)
Fourth year 0 0.0012 (0.0000-0.0029) 0 0.0016 (0.0000-0.0040)
Fifth year 0 0.0012 (0.0000-0.0029) 0 0.0016 (0.0000-0.0040)
Sixth year 0 0.0012 (0.0000-0.0029) 0 0.0016 (0.0000-0.0040)
Seventh year 0 0.0012 (0.0000-0.0029) 0 0.0016 (0.0000-0.0040)
NMSC
First year 13 0.0075 (0.0035-0.0116) 20 0.0069 (0.0028-0.0109)
Second year 14 0.0162 (0.0101-0.0222) 15 0.0158 (0.0092-0.0223)
Third year 10 0.0223 (0.0152-0.0295) 12 0.0254 (0.0165-0.0342)
Fourth year 18 0.0333 (0.0246-0.0419) 9 0.0352 (0.0244-0.0460)
Fifth year 4 0.0360 (0.0269-0.0450) 0 0.0352 (0.0244-0.0460)
Sixth year 4 0.0447 (0.0321-0.0573) 0 0.0352 (0.0244-0.0460)
Seventh year 3 0.0551 (0.0380-0.0723) 0 0.0352 (0.0244-0.0460)
Kaplan-Meier analyses of malignancies included left truncation adjustment for patients with prior etanercept exposure and therefore include
follow-up time from etanercept exposure before the registry.
CI, Confidence interval; NMSC, nonmelanoma skin cancer.
*Includes all events and exposure days that occurred since the first day of treatment with etanercept.
yIncludes only events that occurred during etanercept exposure plus a 30-day risk window after each dosing interval.
Table II. Kaplan-Meier incidence proportions of serious adverse events and serious infectious events
Registry year
Based on observation time* Based on exposure timey
Patients with event, n Cumulative incidence, Q (95% CI) Patients with event, n Cumulative incidence, Q (95% CI)
SAEs
First year 139 0.0633 (0.0531-0.0735) 121 0.0581 (0.0480-0.0682)
Second year 103 0.1163 (0.1024-0.1301) 75 0.1070 (0.0926-0.1215)
Third year 70 0.1557 (0.1397-0.1718) 37 0.1386 (0.1215-0.1558)
Fourth year 53 0.1878 (0.1703-0.2054) 35 0.1771 (0.1565-0.1977)
Fifth year 51 0.2224 (0.2031-0.2417) 19 0.2029 (0.1799-0.2260)
SIEs
First year 45 0.0204 (0.0145-0.0263) 39 0.0184 (0.0127-0.0242)
Second year 25 0.0334 (0.0257-0.0411) 18 0.0301 (0.0222-0.0379)
Third year 17 0.0432 (0.0343-0.0521) 12 0.0408 (0.0310-0.0506)
Fourth year 13 0.0514 (0.0415-0.0613) 5 0.0467 (0.0356-0.0577)
Fifth year 20 0.0650 (0.0536-0.0765) 8 0.0581 (0.0447-0.0716)
CI, Confidence interval; SAEs, serious adverse events; SIEs, serious infectious events.
*Includes all events and exposure days that occurred since the first day of treatment with etanercept.
yIncludes only events that occurred during etanercept exposure plus a 30-day risk window after each dosing interval.
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in either short- and long-term analyses. In addition,
cumulative event rates for SIEs did not differ impor-
tantly across dose groups or over time. In an analysisof 49 clinical trials across etanercept indications,
rates of SIEs were similar between patients receiving
etanercept and control subjects. In that analysis, 49
SIEs were reported in 4361 patients with psoriasis for
Table IV. Standardized incidence ratios based on observed rates from OBSERVE-5 and expected rates from
MarketScan
MarketScan comparator
group, SIR (95% CI)
Malignancy
excluding NMSC* Lymphoma* NMSC*
Infectious event requiring
hospitalizationy
Patients receiving nonbiologic
systemic therapies
0.78 (0.59-1.00) 0.26 (0.03-0.95) 0.54 (0.42-0.69) 0.34 (0.26-0.43)
Patients receiving etanercept 0.89 (0.68-1.15) 0.50 (0.06-1.80) 0.58 (0.45-0.74) 0.51 (0.39-0.66)
Patients receiving
phototherapy
0.74 (0.57-0.96) 0.14 (0.02-0.52) 0.54 (0.42-0.69) 0.41 (0.32-0.53)
Patients receiving other
biologic therapies
0.97 (0.74-1.25) 0.36 (0.04-1.29) 0.46 (0.36-0.58) 0.29 (0.22-0.37)
Patients receiving
methotrexate
0.78 (0.60-1.00) 0.28 (0.03-1.00) 0.55 (0.43-0.70) 0.36 (0.27-0.46)
Patients with psoriasis 0.81 (0.61-1.04) 0.28 (0.03-1.02) 0.62 (0.48-0.79) NA
General MarketScan
populationz
0.95 (0.72-1.22) 0.46 (0.06-1.67) 0.95 (0.73-1.20) NA
Incidence rates from MarketScan were age- and sex-standardized to the OBSERVE-5 population.
CI, Confidence interval; NA, not applicable; NMSC, nonmelanoma skin cancer; SIRs, standardized incidence ratios.
*Analysis based on patient-years of observation.
yAnalysis based on patient-years of exposure.
zComprised all insured individuals who met the eligibility criteria.
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patient-years.9 A meta-analysis of 20 randomized,
controlled trials in patients with psoriatic diseases
(including 14 trials in patients with psoriasis) re-
ported an odds ratio of 0.78 (95% CI 0.38-1.58) for
serious infections in patients with psoriasis treated
with a TNF blocker versus placebo and an odds ratio
of 1.14 (95% CI 0.92-1.40) for overall infections in
patients treated with etanercept versus control.10 In
the 3-year interim analysis of OBSERVE-54 and the
final 5-year results reported here, greater etanercept
exposure was not associated with increased rates of
SAEs or SIEs. Although SIEs are rare events in
patients with psoriasis, physicians should screen
patients for infections before initiating etanercept
and monitor them during therapy.11
Prior studies have suggested that patients with
psoriasis may be at increased risk of malignancy,12
particularly NMSC12 and lymphoma,13 although the
overall risk remains low and the magnitude of
association is modest.13 Psoriasis severity is propor-
tional to the risk of developing NMSC.12 In an
integrated analysis of safety of 7 clinical trials of
etanercept, there was no increase in overall malig-
nancies with etanercept therapy compared with the
psoriasis population.8 In an analysis of 49 clinical
trials across indications, the rate ratio for NMSC
comparing etanercept with placebo in patients with
psoriasis was 2.77 (95% CI 0.59-25.97).9 The SIR
for lymphoma in these trials was 2.01 (95% CI 0.24-
7.27) in patients with psoriasis compared with
Surveillance Epidemiology and End Results data.9
In addition, patients with psoriasis who receivedetanercept appeared to have higher risk of squa-
mous cell carcinomas.9 The meta-analysis of ran-
domized, controlled trials in patients with psoriasis
or psoriatic arthritis receiving TNF blockers showed
no increased risk of malignancy.10 In OBSERVE-5,
rates of malignancies, NMSCs, and lymphomas were
not higher than expected relative to data from
MarketScan.
In contrast to previous phase-III studies, which
had stringent eligibility criteria and excluded pa-
tients with medically significant underlying diseases
and/or were concomitantly taking certain antipsori-
atic medications, enrollment in OBSERVE-5 was
based on the clinical decision by investigators to
continue, initiate, or resume treatment with etaner-
cept. Therefore, this surveillance registry did
not exclude patients for comorbidities or concom-
itant medications, representing real-world use of
etanercept.
A limitation of the study was lack of an internal
comparator. In the absence of a placebo arm,
conclusions about efficacy are less reliable; however,
in large placebo-controlled clinical studies of similar
populations, usually less than 10% of subjects
achieve a status of clear or almost clear with placebo
alone. In addition, the size and duration of the study
may not have been sufficient to detect extremely rare
adverse events that may be related to treatment.
Interpretation of SIRs should consider differences in
data collection methods, sampling designs, and
study populations in a prospective registry versus
an administrative claims database compiled for
billing purposes. Interpretation of safety and
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Fig 2. Plaque psoriasis. Effectiveness outcomes. The per-
centage of psoriasis-affected body surface area (BSA) (A);
percentage of patients with physician global assessment
(PGA) status of clear/almost clear (score 0/1) (B); and
mean Dermatology Life Quality Index (DLQI ) total score
(C) for all patients (squares), patients on continuous
etanercept (ETN ) (circles), and patients on ETN who had
a 0- to 30-day (open triangles) or 0- to 60-day (closed
triangles) gap in therapy. Data are presented as observed
without imputation for missing data.
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122 Kimball et aleffectiveness-related outcomes should take into ac-
count the 42% dropout rate, which may lead to an
underestimation of safety events and an overestima-
tion of effectiveness if discontinuation was related to
these outcomes.In summary, no new or unexpected safety signal
was observed in this 5-year observational study.
Rates of malignancies, lymphomas, NMSC, and in-
fections requiring hospitalization in OBSERVE-5
were not higher than expected relative to data from
MarketScan.
Julia R. Gage, PhD (on behalf of Amgen Inc), and
Dikran Toroser, PhD (Amgen Inc), assisted with writing
and editing the manuscript.
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